Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

89Bio Inc (ETNB)

89Bio Inc (ETNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

89Bio Inc 655 MONTGOMERY STREET SUITE 1500 SAN FRANCISCO CA 94111 USA

www.89bio.com Employees: 93 P: 415-432-9270

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco.

Key Statistics

Overview:

Market Capitalization, $K 2,200,891
Enterprise Value, $K 2,110,561
Shares Outstanding, K 148,308
Annual Sales, $ 0 K
Annual Net Income, $ -367,080 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -111,500 K
EBIT, $ -465,680 K
EBITDA, $ -474,780 K
60-Month Beta 1.27
% of Insider Shareholders 2.60%
Float, K 144,452
% Float 97.40%
Short Interest 6,766
Short Volume Ratio 0.20

Growth:

1-Year Return 81.42%
3-Year Return 69.60%
5-Year Return -39.87%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 85.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.71 on 08/07/25
Next Earnings Date 11/06/25
Earnings Per Share ttm -3.61
EPS Growth vs. Prev Qtr -44.90%
EPS Growth vs. Prev Year -47.92%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ETNB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -94.48%
Return-on-Assets % -80.92%
Profit Margin % 0.00%
Debt/Equity 0.07
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 4.15
Book Value/Share 3.57
Interest Coverage -68.26
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar